Risankizumab is a humanized IgG monoclonal antibody that binds with high affinity and specificity to the p19 subunit and selectively inhibits IL-23, critical for psoriatic inflammation. In phase-3 trials (UltIMMa-1, […]
-
-
Can dermatology employers require employees to receive the COVID-19 vaccine?
-
THE 2020 VISION FOR NEMOLIZUMAB IN ATOPIC DERMATITIS
-
Expression of retinoid receptors in hand eczema.
-
S. aureus Agr Virulence Tied to Atopic Dermatitis in Infants
-
Psoriasis, biological drugs and Coronavirus Disease 2019: Real life experience of two Italian provinces.
